Cost impact of complications in meningococcal disease: Evidence from a United States managed care population

Human Vaccines

Volumn 7, Issue 4, 2011, Pages

  Davis, Keith L ^a   Misurski, Derek ^b   Miller, Jacqueline ^c   Karve, Sudeep ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b GLAXOSMITHKLINE   (United States)

^c NONE

Author keywords

Economic burden; Health care utilization; Invasive meningococcal disease; Sequelae

Indexed keywords

ADOLESCENT; ADRENAL HEMORRHAGE; ADULT; ARTICLE; ATAXIA; BLINDNESS; BRAIN HYPOXIA; CHILD; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CRANIAL NERVE PARALYSIS; EPILEPSY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEARING LOSS; HEMIPARESIS; HUMAN; HYDROCEPHALUS; INFANT; INFECTIOUS COMPLICATION; LEARNING DISORDER; LIMB AMPUTATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MENTAL DEFICIENCY; PREDICTION; PRESCHOOL CHILD; QUADRIPLEGIA; RETROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SKIN NECROSIS; STROKE; UNITED STATES; ECONOMICS; MIDDLE AGED; NEWBORN; STATISTICS; UTILIZATION REVIEW;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MANAGED CARE PROGRAMS; MENINGOCOCCAL INFECTIONS; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 79955035721     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.4.14434     Document Type: Article

References (47)

1. Butler KM. Meningococcal meningitis prevention programs for college students: a review of the literature. Worldviews Evid Based Nurs 2006; 3:185-93. (Pubitemid 44950375)
2. Caugant DA, Maiden MC. Meningococcal carriage and disease - population biology and evolution. Vaccine 2009; 27:64-70; E-pub 2009 May 21.
3. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821-32. (Pubitemid 39238387)
4. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
5. Davies AL, O'Flanagan D, Salmon RL, Coleman TJ. Risk factors for N. meningitidis carriage in a school during a community outbreak of meningococcal infection. Epidemiol Infect 1996; 117:259-66. (Pubitemid 26345235)
6. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis 2010; 50:37-44.
7. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:51-63; E-pub 2009 May 27.
8. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in N. meningitidis disease epidemiology in the United States 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
9. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network: Neisseria meningitidis 2008. 2009. Available at: http://www.cdc.gov/abcs/ reports-findings/ survreports/mening08.html. Accessed September 28, 2010.
10. Caro JJ, Möller J, Getsios D, Coudeville L, El-Hadi W, Chevat C, et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health 2007; 7:130.
11. Shepard CW, Ortega-Sanchez IR, Scott RD, 2nd, Rosenstein NE. ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics 2005; 115:1220-32.
12. Centers for Disease Control and Prevention. Vaccination coverage among adolescents aged 13-17 years - United States 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1100-3.
13. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50:45-53.
14. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9:285-98.
15. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC Recommendations and Reports 2005; 54.
16. Centers for Disease Control and Prevention. Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010; 59:273.
17. American Academy of Pediatrics. 2010 immunization schedules. 2010. Available at: http://www.aap.org/ immunization/IZSchedule.html. Accessed September 28, 2010.
18. Borg J, Christie D, Coen PG, Booy R, Viner RM. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. Pediatrics 2009; 123:502-9.
19. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada 1990-1994. Clin Infect Dis 1998; 26:1159-64.
20. Erickson LJ, De Wals P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin Infect Dis 2001; 33:737-9. (Pubitemid 32762952)
21. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:317-28.
22. Edmond K, Dieye Y, Griffiths UK, Fleming J, Ba O, Diallo N, et al. Prospective cohort study of disabling sequelae and quality of life in children with bacterial meningitis in urban Senegal. Pediatr Infect Dis J 2010; 29:1023-9; [E-pub ahead of print].
23. Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 2007; 25:5945-57; E-pub 2007 May 15.
24. Getsios D, Caro I, El-Hadi W, Caro JJ. Assessing the economics of vaccination for N. meningitidis in industrialized nations: a review and recommendations for further research. Int J Technol Assess Health Care 2004; 20:280-8. (Pubitemid 39079563)
25. Miller MA, Shahab CK. Review of the cost effectiveness of immunisation strategies for the control of epidemic meningococcal meningitis. Pharmacoeconomics 2005; 23:333-43. (Pubitemid 40677052)
26. Welte R, Trotter CL, Edmunds WJ, Postma MJ, Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 2005; 23:855-74. (Pubitemid 41317422)
27. Naess A, Halstensen A, Nyland H, Pedersen SH, Møller P, Borgmann R, et al. Sequelae one year after meningococcal disease. Acta Neurol Scand 1994; 89:139-42. (Pubitemid 24095270)
28. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Med 2009; 7:47.
29. Tsolia MN, Theodoridou M, Tzanakaki G, Vlachou V, Mostrou G, Stripeli F, et al. Invasive meningococcal disease in children in Greece: comparison of serogroup A disease with disease caused by other serogroups. Eur J Clin Microbiol Infect Dis 2006; 25:449-56. (Pubitemid 44078597)
30. de Souza AL, de Oliveira AC, Romano CC, Sztajnbok J, Duarte AJ, Seguro AC. Interleukin-6 activation in ischemic stroke caused by N. meningitidis serogroup C. Int J Cardiol 2008; 127:160-3; E-pub 2007 Aug 30.
31. Gironell A, Domingo P, Mancebo J, Coll P, Martí- Vilalta JL. Hemorrhagic stroke as a complication of bacterial meningitis in adults: report of three cases and review. Clin Infect Dis 1995; 21:1488-91. (Pubitemid 26066647)
32. Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health 1995; 85:843-5.
33. O'Brien JA, Caro JJ, Getsios D. Managing meningococcal disease in the United States: hospital case characteristics and costs by age. Value Health 2006; 9:236-43. (Pubitemid 44126778)
34. Bickston SJ, Waters HC, Dabbous O, Tang BI, Rahman M. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm 2008; 14:352-62. (Pubitemid 351890850)
35. Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, et al. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin. Curr Med Res Opin 2010; 26:355-63.
36. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008; 30:1375-84.
37. Heyderman RS, Ben-Shlomo Y, Brennan CA, Somerset M. The incidence and mortality for meningococcal disease associated with area deprivation: an ecological study of hospital episode statistics. Arch Dis Child 2004; 89:1064-8.
38. Barquet N, Domingo P, Caylà JA, González J, Rodrigo C, Fernández-Viladrich P, et al. Meningococcal disease in a large urban population (Barcelona 1987- 1992): predictors of dismal prognosis. Barcelona Meningococcal Disease Surveillance Group. Arch Intern Med 1999; 159:2329-40.
39. Buysse CM, Raat H, Hazelzet JA, Hulst JM, Cransberg K, Hop WC, et al. Long-term health status in childhood survivors of meningococcal septic shock. Arch Pediatr Adolesc Med 2008; 162:1036-41.
40. Buysse CM, Oranje AP, Zuidema E, Hazelzet JA, Hop WC, Diepstraten AF, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child 2009; 94:381-6; E-pub 2009 Jan 15.
41. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40:373-83. (Pubitemid 17055592)
42. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43:1130-9. (Pubitemid 41587600)
43. Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care 2009; 47:109-14.
44. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and productivity costs associated with diabetic patients with macrovascular comorbid conditions. Diabetes Care 2009; 32:2187-92; E-pub 2009 Sep 3.
45. Wedderburn RWM. Quasi-likelihood functions, generalized linear models and the Gauss-Newton method. Biometrika 1974; 61:439-47.
46. Manning WG. The logged dependent variable, heteroscedasticity and the retransformation problem. J Health Econ 1998; 17:283-95. (Pubitemid 28300217)
47. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20:461-94.